Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | PTPRF | P10586 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL30486758 | 0.98 | KCNH3 (0.62) | KCNH3MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4241915 | 0.91 | HTT (0.64) | KCNH3CYP1A2POLBGAAL3MBTL1 | |
| SCHEMBL10055033 | 0.89 | LMNA (0.61) | KCNH3MEN1KMT2APOLBGAA | |
| SCHEMBL6419238 | 0.89 | LMNA (0.61) | KCNH3MEN1KMT2APOLBGAA | |
| SCHEMBL2065031 | 0.89 | CYP1A2 (0.69) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11510992 | 0.88 | FFAR1 (0.63) | KCNH3MEN1KMT2AGAAL3MBTL1 | |
| Propionic Acid SCHEMBL11468427 | 0.86 | FFAR1 (0.59) | KCNH3MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6692354 | 0.85 | PPARA (0.54) | KCNH3MEN1KMT2AMAOB | |
| SCHEMBL22628164 | 0.84 | HTT (0.71) | KCNH3MEN1CYP1A2CYP3A4CYP2C9 | |
| N-Benzylaniline SCHEMBL7840 | 0.84 | HTT (0.71) | KCNH3MEN1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119701982-A | Application of niobium oxide supported copper catalyst in synthesis of secondary amine or derivative thereof from aromatic nitro compound and benzyl alcohol compound | 兰州大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-112409188-B | Method for synthesizing N-alkylamine | 南京理工大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-112206777-B | Preparation method and application of carbonized octahedral material HKUST-1-400 | 三峡大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-109046463-B | Bidentate aza-carbene-manganese catalyst, preparation method and alkylation synthesis application thereof | 中山大学 | 2021-05-04 | — | — | CN | disclosed |
| CN-108380245-B | Bidentate phosphorus-aza-carbene p-cymene type ruthenium complex catalyst, preparation method and synthesis application thereof | 中山大学 | 2020-06-09 | — | — | CN | disclosed |
| EP-3006432-B1 | 2,3-BUTANEDIAMIDE EPOXIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACAD MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2017-11-15 | — | — | EP | disclosed |
| US-9630957-B2 | 2,3-butanediamide epoxide compound and preparation method and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-04-25 | — | — | US | disclosed |
| US-20160115160-A1 | 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2016-04-28 | — | — | US | disclosed |
| EP-3006432-A1 | 2,3-BUTANEDIAMIDE EPOXIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2016-04-13 | — | — | EP | disclosed |
| CN-103004006-B | Additive for nonaqueous electrolyte, nonaqueous electrolyte, and electricity storage device | SUMITOMO SEIKA CHEMICALS | 2014-02-19 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006060731-A2 | USE OF ATAZANAVIR FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY UGT1A1 | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-1089988-A4 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2005-01-19 | — | — | EP | disclosed |
| CN-1185259-C | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2005-01-19 | — | — | CN | disclosed |
| US-6639023-B1 | Such as 4-hydroxy, sulfonic acid or sulfonyl chloride-2,3,5,6-tetrafluorobenzamidomethyl-polystyrene resin; solid phase synthesis | AVENTIS PHARMACEUTICALS INC. | 2003-10-28 | — | — | US | disclosed |
| CN-1306524-A | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2001-08-01 | — | — | CN | disclosed |
| EP-1089988-A1 | FLUOROPHENYL RESIN COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067228-A1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-4152452-A | N-BENZYLANILINE AND DERIVATIVES | WILLIAM H. RORER, INC. (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115160-A1 | 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof | ECE2, GNE, EPHX2 | KCNH3 1897/4885MEN1 2462/4885CYP1A2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.